Physician profile
Robert C Udell
NPI 1952375560
$10,729.61
in general payments reported to CMS, 2019-2025
50 companies · $973 in 2025
The $973 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,049 · 2020: $634 · 2021: $1,864 · 2022: $1,737 · 2023: $2,451 · 2024: $2,022 · 2025: $973.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,437 · Education: $8.42.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,437.44 |
| Education | $8.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $827.56 | 2019-2025 | Tagrisso, Datroway, Imfinzi |
| E.R. Squibb & Sons, L.L.C. | $721.36 | 2022-2024 | Reblozyl, Opdivo |
| Genentech USA, INC. | $637.60 | 2019-2023 | Lunsumio |
| Amgen INC. | $605.12 | 2019-2023 | Repatha |
| Janssen Biotech, INC. | $477.81 | 2021-2024 | Rybrevant |
| Bayer Healthcare Pharmaceuticals INC. | $419.86 | 2022-2024 | |
| Genzyme Corporation | $399.34 | 2021-2024 | |
| Daiichi Sankyo INC. | $393.36 | 2020-2024 | Enhertu |
| Incyte Corporation | $345.71 | 2019-2024 | Jakafi, Monjuvi, Pemazyre |
| Kite Pharma, INC. | $328.80 | 2021-2023 | Yescarta |
| Seagen INC. | $327.40 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $301.04 | 2019-2023 | Keytruda |
| Abbvie INC. | $273.29 | 2019-2024 | Venclexta |
| Glaxosmithkline, LLC. | $248.46 | 2021-2024 | Zejula |
| Gilead Sciences, INC. | $246.38 | 2023-2024 | Trodelvy |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Udell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.